Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2006-04-04
2006-04-04
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S007100, C435S069100
Reexamination Certificate
active
07022482
ABSTRACT:
The invention concerns the use of a protein derived from cancer cells, virus-infected cells or immune-defence cells or a fragment of said protein, characterized in that said protein is initially an immunosuppressive and/or angiogenic protein with local activity and said properties are inactivated by at least 70%, through a physical and/or chemical treatment, by genetic recombination or by adjuvant conditioning, said treatment preserving its property of being identified by antibodies directed afainst said protein, and preserving sufficient immunogenic properties for generating antibodies neutralizing or blocking said native protein, to obtain a medicine for use as local anti-immnumosuppression and/or anti-angiogenic agent as an anticancer agent. The invention also concerns the resulting immunogenic compounds, their preparation method and their uses.
REFERENCES:
patent: 5308612 (1994-05-01), Lee
patent: 5874089 (1999-02-01), Schlegel et al.
patent: 6093405 (2000-07-01), Zagury et al.
patent: 6132721 (2000-10-01), Zagury et al.
patent: 6200575 (2001-03-01), Zagury et al.
patent: 6420141 (2002-07-01), Zagury et al.
patent: 6455045 (2002-09-01), Zagury et al.
patent: 95/31999 (1995-11-01), None
patent: 96/27389 (1996-03-01), None
“Chemical Abstracts”, vik. 130, No. 21 1999 Columbus, Ohihio, US; abstract No. 280480, A. Gringeri et al; Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients: XP002114179.
J. Rappaport et al; “HIV-1 Tat toxoid: Rationale for a Tat vaccine and results of a phase I clinical trial.” Jornal of Neurovirology, vol. 4, No. 3, Apr. 1996, pp. 97-103, XP002106209.
M. Boursnell et al; “Constaruction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immuntherapy of servical cancer,” VACCINE, vol. 14 No. 16, Nov. 1996. pp. 1485-1494, XP002106210.
Y. Tanaka et al; “Production of a recombinant human T-cell leukemia virus type—I trans-activator (tax 1) antigen and its utilization for generation of monoclonal antibodies against various epitipes on the tax 1 antigen,” International Journal of Cancer, vol. 48, No. 4, Jun. 19, 1991, pp. 623-630, XP002106211.
K. Speidel et al; “Priming of cytotoxic T lymphocytes by five heat-aggregated antigents in vivo:conditions, efficiency, and relation to antibody responses,” European Journal of Immunology, vol. 27, No. 9, Sep. 1997, pp. 239102399, XP002106212.
H.Le Buanec et al; “A prophylactic andd therapeutic AIDS caccine containing as a component the innocuous Tat toxoid.” Biomedicine and Pharmacotherapy, vol. 52, No. 10, 1998 pp. 431-435, XP002106213.
A. Gringeri et al; “Tat toxoid as a comp9nent of a preventice vaccine in seronegative subjects.” Journal of Acuired Immune Deficiciency Syndromes and Human Retrovirology, vol. 20, No. 4, Apr. 1, 1999 pp. 371-375, XP002106214.
Murphy et al., Fields Virology, 1990 2ndEd., Chapter 19, pp. 480-482.
Greenstone et al., Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model, Proc. Natl. Acad. Sci. USA, 95:1800-1805 (1998).
Wang-Johanning et al., Intracellular expression of a single-shain antibody directed against human papillomavirus type 16E7 oncoprotein achieves targeted antineoplastic effects, Cancer Res. 58(9):1893-1900 (1998).
Asano et al., Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121, Cancer Res., 55(22):5296-5301 (1995).
Borysiewicz et al., A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer, LANCET, 347(9014):1523-1527 (1996).
Herd et al., E7 oncoprotein of human papillomavirus type 16 expresse constitutitively in the epidermis has no effect on E7-specific B-or Th-repertoires or on the immune response induced or sustained after immunization with E7 protein, VIROLOGY, 231(1):155-165 (1997).
Harbiharan et al., Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in Provax, Int. J, Oncol., 12(6):1229-1235 (1998).
Zagury Daniel A.
Zagury Jean-Francois
Browdy and Neimark PLLC
Neovacs
Salimi Ali R.
LandOfFree
Use of immunogenic immunosuppressive and/or angiogenic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of immunogenic immunosuppressive and/or angiogenic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of immunogenic immunosuppressive and/or angiogenic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3584718